CD163 and neoplasm: Results show that tumours from patients with rs22(GC)+rs29(TC) genotype had significantly more CD163+ Mɸ (median 3.19–6.14 fold) compared to rs22(CG), rs22(CC), rs22(GG) and rs22(CC)+rs30(AG) genotypes (Figure 3a and Table S3).